News
New call for submissions
Exploring the Gut-Brain Axis. Implications for Neurological and Psychiatric Disorders – Mechanisms, Biomarkers, and Emerging Therapies
The gut–brain axis represents a rapidly evolving frontier in medicine, shedding new light on how gut microbiota and their metabolites influence brain development, function, and disease. Its importance is increasingly recognized across neuroscience, psychiatry, immunology, endocrinology, and translational medicine.
This special issue of Advances in Clinical and Experimental Medicine seeks to consolidate high-impact, novel research that advances our mechanistic and clinical understanding of gut–brain crosstalk, with a particular focus on its relevance for neurological and psychiatric disorders. We welcome interdisciplinary submissions that go beyond descriptive associations and offer insights into molecular mechanisms, predictive biomarkers, sex-specific effects, response to therapy, and new avenues for clinical intervention.
Authors are encouraged to submit original research, meta-analyses, or systematic/scoping reviews related to (but not limited to) the following areas of interest:
- Microbiota and neurodevelopment: Mechanistic and clinical studies on how gut microbes influence brain development, connectivity, and vulnerability to disorders like ASD and ADHD.
- Gut dysbiosis in psychiatric disorders: Novel links between altered microbial composition and psychiatric conditions such as depression, anxiety, schizophrenia, and bipolar disorder.
- Molecular communication pathways: Exploration of immune, endocrine, vagal, and epigenetic mechanisms mediating gut–brain signaling beyond known metabolic routes.
- Sex-specific differences in the gut–brain axis: Studies focusing on gender-related variations in microbiota composition, signaling, and effects on neuropsychiatric trajectories.
- Microbiota–drug interactions: How gut microbes influence drug metabolism, therapeutic response, and treatment tolerability in psychiatric patients.
- AI and computational modeling: Predictive modeling of brain disorders or treatment outcomes based on microbiome and host data using artificial intelligence.
- COVID-19 and post-viral neuropsychiatric sequelae: Investigations into the role of gut dysbiosis in persistent cognitive and mood symptoms following COVID-19 and similar infections.
- Microbiome-based therapies: Evaluation of targeted interventions - such as psychobiotics, prebiotics, dietary patterns, and FMT – in mental health care.
- Metabolomic profiling: Identification of gut-derived bioactive compounds that modulate brain function via neurotransmitter or hormonal pathways.
- Gut barrier integrity and neuroinflammation: Role of increased intestinal permeability and systemic inflammation in dementia, mood disorders, and neurodegeneration.
- Translational and clinical studies: Implementation research, including clinical trials, safety data, treatment biomarkers, and regulatory perspectives.
.jpg)
Meet the author of our latest editorial!
Victor Geller
READ THE EDITORIAL
MINI-INTERVIEW
1. How accurate could be systemic inflammation markers in diagnosing and assessing malignancies?
Since the introduction of the Systemic Immune Inflammation Index (SII), complete blood count-derived inflammation indices (CBC-DIIs) have been extensively researched in the field of tumor malignancies. In terms of diagnostic precision, in prospective cohorts, a single CBC-DII distinguishes malignant from benign lesions with areas under the receiver operating characteristic (ROC) curve clustered in the 0.68–0.77 range. When the same indices are incorporated into multivariable algorithms that incorporate established markers (e.g., CA-125/HE4 in gynecology or CT/MRI features in pancreatic lesions), overall accuracy rises into the 0.85–0.90 range, which is generally considered clinically actionable.
In the baseline prognostic value, meta-analyses across solid tumors consistently demonstrate that patients with the highest CBC-DII ranges encounter a 40–100% increase in the risk of adverse events. Depending on the tumor type, a 1.4 to 2.4 rise in unfavorable overall survival is observed for high CBC-DII values. Similarly, cancer-specific and progression-free end-points exhibit a comparable pattern. Dynamic CBC-DII data collected during longitudinal observations enhance risk estimation.
Stand-alone DII measurements provide modest diagnostic utility, but when integrated with existing biomarkers or imaging modalities, they elevate discrimination to guideline-quality standards. Prognostically, an unfavorable baseline index or an early post-treatment increase should prompt intensified surveillance and consideration of intensified—or alternative—systemic therapy. At the same time, favorable or declining values can support de-escalation. Additionally, elucidating correlations between specific tumors and their development, progression, and variations in CBC parameters may contribute to enhanced accuracy and specificity of CBC-DII.
2. How such markers can help in diagnosing and treating depression?
CBC-DIIs are bridging the gap between laboratory immunology and clinical psychiatry. A converging literature demonstrates that higher CBC-DIIs are consistently associated with increased depressive symptom severity, higher probabilities of major depressive disorder diagnoses, diminished antidepressant efficacy, and, over time, early indications of relapse. While the absolute discriminative power of a single CBC-DII is modest, its clinical significance arises when these values are utilized to identify the inflamed depression phenotype, guide the selection of anti-inflammatory or conventional antidepressant strategies, and monitor whether an intervention is effective.
Baseline inflammatory load forecasts individuals at risk of failing to remit on initial-line pharmacotherapy. In treatment-resistant bipolar depression, high pre-treatment SIRI predicted elevated Hamilton Depression scores eight weeks after escitalopram–celecoxib augmentation, while low SIRI indicated symptomatic improvement. More broadly, narrative and systematic reviews suggest that elevated CBC-DIIs identify a subgroup more likely to benefit from add-on anti-inflammatory agents compared to additional serotonergic escalation.
Changes in CBC-DIIs correspond with symptom trajectories. Studies indicate that a decreasing SII correlates with mood recovery, while a rebound precedes depressive relapse. This temporal association enables practitioners to ascertain that an intervention is targeting its immunological component and to identify early depression relapse, particularly beneficial in settings where comprehensive psychiatric evaluation at each visit is impractical.
By augmenting depression symptom scales with a routinely accessible inflammatory snapshot, CBC-DIIs may advance psychiatry a step toward precision medicine, enabling clinicians to discern the inflammatory depression subtype, assign patients to the most suitable intervention, and monitor both biological and psychological recovery. A significant advancement would be the development of a depression-specific CBC-DII capable of supplanting conventional depression scores.
3. How such markers can help in increased risk of type 2 diabetes mellitus?
The development of type 2 diabetes (T2DM) is linked to chronic systemic low-grade inflammation, where CBC-DIIs reflect this inflammatory state. Research indicates that elevated CBC-DIIs levels are independently associated with an increased risk and severity of diabetic foot ulcers, diabetic kidney disease, diabetic retinopathy, and other complications of T2DM. Furthermore, diabetic patients with elevated CBC-DIIs levels exhibited poorer clinical outcomes. The correlation between CBC-DIIs and various diabetic complications and outcomes suggests their potential as a biomarker for early detection and risk stratification, potentially leading to more timely and effective interventions.
Insulin resistance, a pivotal factor in the development of T2DM, can also contribute to inflammation, perpetuating a vicious cycle. Research has demonstrated a strong positive correlation between systemic inflammation, HOMA-IR values, and CBC-DIIs levels in individuals with prediabetes and diabetes. Consequently, understanding the interplay between systemic inflammation and insulin resistance is crucial for the effective prevention and management of T2DM.
Additionally, research has demonstrated a substantial negative correlation between inadequate glycemic control and red blood cell count, hemoglobin, hematocrit, mean corpuscular hemoglobin, and a positive correlation with red blood cell distribution width and platelet count, particularly in individuals with T2DM. These observations suggest the potential for the development of CBC-DIIs with enhanced specificity for detecting diabetes and monitoring glycemic control.
New statistical guidelines
Editors of Adv Clin Exp Med are well aware that correct analysis of statistical data and reporting the results of such analysis is not easy even for experienced researchers, because we are dealing with really, not only ostensibly complicated matters. Specialists from the Centre for Statistical Analysis at the Wroclaw Medical University want to provide you as much help and guidance as possible, and have prepared these detailed guidelines for all authors wishing to submit their manuscripts to our journal.
Should you have any questions regarding statistics in Adv Clin Exp Med, don't hesitate to get in touch with our managing editor, Marek Misiak [marek.misiak@umw.edu.pl] – an online meeting with our statistical editors can be organized.
If you have questions regarding our instructions for authors, please attend our monthly editorial duty hour.
14th EURIPA Rural Health Forum
Rural Reformation: Meeting Wellbeing and Healthcare Needs in Rural Communities
26–28 June 2025
Wittenberg, Saxony-Anhalt, Germany
European Rural and Isolated Practitioners Association (EURIPA) is a representative network organisation founded by family doctors to address the health and well-being needs of rural communities and the professional needs of those serving them across Europe. It represents a growing network of rural practitioners and organisations working together to disseminate good practice, initiate research, and influence policy.
Our journal has become a media partner of this conference.
.jpg)
Meet the author of our latest editorial!
Prof. Marek Konop
READ THE EDITORIAL
MINI-INTERVIEW
1. What can change for patients should keratin wound dressings enter wide use in clinical practice?
The introduction of keratin-based wound dressings into standard clinical practice could significantly improve patient outcomes, particularly for individuals with chronic or difficult-to-heal wounds, such as diabetic ulcers, venous and arterial ulcers, burns, and wounds in patients with epidermolysis bullosa or pyoderma gangrenosum. Keratin biomaterials offer enhanced biocompatibility, promote rapid re-epithelialisation, boost angiogenesis, and support the shift towards regenerative healing phenotypes (such as encouraging M2 macrophage polarisation). Although clinical studies are still limited, they have demonstrated faster wound closure, reduced inflammation, improved quality of newly formed tissue, and increased patient comfort and quality of life. For example, keratin dressings have shown particular benefit in wounds resistant to standard treatments, often resulting in complete healing and decreasing the need for secondary dressings. Additionally, keratin’s unique bioactivity and low immunogenicity diminish the risk of adverse reactions, which is especially significant in patients with chronic inflammation or comorbidities.
2. Are there any dangers than can be uncovered during further clinical trials involving larger groups of patients – or is merely a confirmation of such wound dressings needed for wider application?
While preclinical and early clinical studies show that keratin wound dressings are safe, biocompatible, and well-tolerated, large-scale clinical trials are still necessary to confirm their safety and effectiveness across a wider and more diverse patient population. Potential risks that could be identified in such trials include rare allergic reactions, unexpected immunogenic responses, or specific complications in patients with atypical wound conditions. There is also the hypothetical risk of encouraging bacterial colonisation if the keratin dressing is not combined with proper antimicrobial strategies, as some keratinolytic bacteria may flourish in keratin-rich environments (although current studies indicate that keratin dressings have some natural antimicrobial properties). However, to date, no major safety concerns have been reported in published clinical studies, and most evidence suggests that larger trials would mainly serve to confirm the efficacy, ideal use cases, and long-term results of keratin dressings rather than uncovering significant new risks.
3. How would the application of keratin wound dressings look like in practice?
In clinical practice, keratin wound dressings would be used similarly to other advanced wound care products. They are available in various forms—hydrogels, matrices, foams, and gels - that can be chosen based on wound characteristics (e.g., exudate level, chronicity, presence of infection). For instance, hydrogels and gels are suitable for dry or minimally exuding wounds, while foams and matrices are preferred for highly exuding wounds. The application involves cleansing the wound, selecting a suitable keratin-based product, and applying it directly to the wound bed. Dressings are usually changed according to wound type, exudate levels, and manufacturer recommendations, with some keratin dressings suitable for daily use and others remaining in place for several days. Handling and use require no specialised training beyond standard wound care protocols, making them accessible in a variety of clinical settings.
6th International Wroclaw Scientific Meetings
Registration is now open for 6th International Wroclaw Scientific Meetings, which will take place on October 2–4, 2025, at the Wroclaw Medical University in Wrocław, Poland.
The 6th International Wroclaw Scientific Meetings is an event organized by scientists from the Faculty of Pharmacy of Wroclaw Medical University. The conference is addressed to young researchers. It is a unique opportunity to present their work in pharmacy, biology, medicine, toxicology, engineering, and technology.
Dates: October 2–4, 2025
Location: The Faculty of Pharmacy, Wroclaw Medical University, Wroclaw, Poland
Focus Areas: Pharmacy, Biology, Medicine, Toxicology, Engineering, Technology
Abstract submission deadline: July 31, 2025
MORE INFORMATION
https://konferencje.umw.edu.pl/6iwsm2025/
Thank you for your contribution to the success of Advances in Clinical and Experimental Medicine
We are pleased to share that, while the Impact Factor of Advances in Clinical and Experimental Medicine has remained at a comparable level to the previous year (5-Year Impact Factor has not changed – 2.0), CiteScore and other Scopus-based metrics have shown growth (from 3.7 for 2023 to 4.3 in 2024), reflecting the consistent strength and influence of the research we publish.
In a time when many journals face challenges with volatility in scientometric indicators, our ability to maintain a stable and high level of quality is a success in itself. This achievement underscores the robustness of our editorial processes and the relevance of the work we collectively advance.
We would like to express our deepest appreciation to all Authors, Reviewers, Section Editors, Scientific Committee members, and WMU Press for their exceptional commitment, expertise, and collaboration. Your contributions not only sustain the scientific integrity of the journal, but also drive forward its reputation and reach.
Together, we continue to build a journal that upholds academic excellence and delivers meaningful impact on clinical and experimental medicine. Thank you for being an integral part of this ongoing success.
Warm regards,
The Editorial Team
Advances in Clinical and Experimental Medicine
Meeting with a statistician – how to use statistics in a scientific article?
WHEN?
June 25 (Wednesday), 9:00 CET
WHERE?
MS Teams platform
Dr. Krzysztof Kujawa, head of the Centre for Statistical Analysis at Wroclaw Medical University, will share essential insights on:
• how to avoid common statistical pitfalls,
• what editors look for in methodology sections,
• and why sound stats = higher acceptance rates.
Bring your questions! The session is open to everyone, especially researchers in medicine, pharmacy & health sciences.
It is worth noting that the rules discussed are not specific only to our journal – many scientific journals use some form of verification of the statistical methods used in the submitted papers. At the meeting, you will be able to discuss this with our expert.
Scientific Research in service of equality and mental health
In honor of Pride Month (June 2025), we would like to highlight an ongoing Call for Submissions in Advances in Clinical and Experimental Medicine focused on LGBTQ+ health:
Call for Submissions: Health Equity and Innovations in LGBT+ Care
https://advances.umw.edu.pl/en/lgbt
We support high-quality, evidence-based research in this field, grounded in data and scientific method, free from ideology, and focused on understanding the medical, psychological and social determinants of health among LGBTQ+ individuals.
This reflects our commitment to inclusive, empathic and scientifically sound healthcare.
The right to medical care, often understood as the right to health, is a fundamental human right recognized in international law. It also includes the right to access quality health services without discrimination, ensuring that everyone has access to necessary medical care.
Meet the author of our latest editorial!
Assoc. Prof. Hao Zhang
READ THE EDITORIAL
https://advances.umw.edu.pl/en/article/2025/34/5/669/
SHORT BIO
https://ojs.umw.edu.pl/files/acem/Hao%20Zhang-CV.pdf
MINI-INTERVIEW
1. Is a universal "cure for cancer" theoretically possible?
While a single "cure for all cancers" is unlikely due to the vast heterogeneity of cancer types and their unique genetic, epigenetic, and microenvironmental drivers, theoretically, advancements in understanding common mechanisms (e.g., immune evasion, angiogenesis, or metabolic reprogramming) could lead to broader therapies. For example, immunotherapies such as checkpoint inhibitors or CAR-T cells target mechanisms shared by multiple types of cancer. However, cancer's complexity, such as tumor evolution and resistance, means a universal cure may remain elusive. Instead, the future likely lies in precision medicine, which combines tailored therapies for individual patients or specific cancer subtypes.
2. Why are tumors adaptable to treatments?
Genetic heterogeneity: Rapid mutations and clonal evolution allow resistant subpopulations to survive.
Epigenetic plasticity: Dynamic gene expression changes enable survival under stress (e.g., chemotherapy).
Cancer stem cells: A subset of cells with self-renewal capacity resists therapies and regenerates tumors.
Tumor microenvironment: Protective niches (e.g., hypoxia, stromal interactions) shield cancer cells.
Immune evasion: Mechanisms like PD-L1 expression suppress anti-tumor immunity.
Selective pressure: Treatments eliminate sensitive cells, leaving resistant clones to proliferate.
3. How can AI revolutionize cancer treatment?
Early detection: Analyzing imaging (e.g., mammograms, MRIs) for subtle patterns missed by humans.
Precision oncology: Predicting drug responses by integrating genomic, clinical, and lifestyle data.
Drug discovery: Accelerating compound screening and identifying novel targets via machine learning.
Treatment optimization: Simulating outcomes of combination therapies or radiation dosing.
Research acceleration: Mining vast datasets (e.g., clinical trials, publications) to uncover hidden insights.
Challenges remain, such as data quality and ethical concerns, but AI’s potential to enhance diagnostics, personalization, and efficiency is transformative.
New Cite Score
We proudly inform our readers that our Scopus CiteScore has increased from 3.7 for 2023 to 4.3 for 2024. Our current Scimago Journal Rank (SJR) is 0.598 and Source Normalized Impact Paper (SNIP) is 0.626. Steadily rising bibliometric scores of Advances in Clinical and Experimental Medicine confirm our expanding influence among scientific medical journals.
This increase is not just a number – it’s a signal of growing influence, academic value, and future potential.We welcome new, high-impact submissions from researchers worldwide who wish to share their work with a growing global audience!
We would like to express our sincere gratitude to all Authors, Reviewers, Section Editors, Members of the Scientific Committee, and the Editorial Team at Wroclaw Medical University Press, whose dedication and professionalism have contributed to this achievement.
Meet the author of our latest editorial!
Prof. Anthony Dissen EdD, MPH, MA, RDN, CPH
✔️READ THE EDITORIAL
https://advances.umw.edu.pl/en/article/2025/34/5/663/
✔️SHORT BIO
https://ojs.umw.edu.pl/files/acem/Anthony%20Dissen_Brief%20CV.pdf
✔️MINI-INTERVIEW
1. What are the main reasons for knowledge gaps concerning nutrition-related needs of the transgender and gender non-conforming (TGNC) population?
There are a few different important points that contribute to this knowledge gap regarding nutrition-related needs and considerations for the TGNC population. First, TGNC are often underrepresented or outright absent from nutrition research and assessment, so we often see them not including in study samples. Second, a great deal of health and medical research for TGNC people continues to focus on gender-affirming care, which is, of course, crucially important, but it also neglects the more complete and total understanding of all facets of TGNC-related needs and care, including food and nutrition. And lastly, many healthcare professionals, and nutrition professionals in particular, are not informed or aware of how gender-affirming care impacts various aspects of a person’s physiologic needs, and as a result, are not considering the multiple ways in which these care interventions impact other needs and requirements for the individual.
2. Is stigmatization and bias towards TGNC people a significant problem in the USA? What are the key manifestations of such bias?
Unfortunately, stigmatization, bias, and discrimination continue to be common in the USA for TGNC people. It has been estimated that nearly half of all TGNC in the United States of America experience discrimination in public spaces (restaurants, shops, etc.) and even in their interactions with healthcare professionals, including deadnaming, not respecting pronouns, and both implicitly and explicitly showing discomfort and disagreement with their TGNC identity. Oher key manifestations of bias including underemployment, housing discrimination, physical and verbal assaults, and harassment. This also manifests in the form of microaggressions, such as making insensitive comments, rude remarks, jokes, or negative assumptions.
3. How does HRT influence nutrition-related needs in TGNC people?
One of the most important ways in which HRT influences the nutrition-related needs of TGNC people is through changes to basal metabolic rate due to changes in body composition. HRT that is more “masculinizing” tends to increase skeletal muscle mass, which increases basal metabolic rate and increases energy needs and requirements, whereas HRT that is more “feminizing” tends to decrease skeletal muscle mass and increase adipose tissue mass, leading towards a decrease in energy requirements. This change in metabolic requirements can also influence levels of appetite and hunger, which may be unfamiliar or even uncomfortable to people who are used to feeling greater or lower levels of hunger daily. Another important consideration is distribution of adipose tissue, as HRT can significantly change distribution of adipose tissue within the body, which may lead to an increased potential risk of cardiac disease if adipose tissue is becoming more located within the trunk of the body. As a result, changes to saturated fat intake and may be necessary to prevent increases in serum LDL-C levels. Additionally, HRT can influence bone mineral density and may require increased intakes of calcium and vitamin D to prevent loss of bone mineral density over time.
SCImago Journal Rank (SJR) 2024
We are proud to announce that Advances in Clinical and Experimental Medicine has been classified in Q1 in the latest SCImago Journal Rank (SJR 2024), with an SJR score of 0.598.
With a solid H-index of 49, our journal continues to provide high visibility and impact for authors publishing in the fields of internal medicine, pharmacology, and translational biomedicine.
We would like to express our sincere gratitude to all Authors, Reviewers, Section Editors, Members of the Scientific Committee, and the Editorial Team at Wroclaw Medical University Press, whose dedication and professionalism have contributed to this achievement.
https://www.scimagojr.com/journalrank.php
New call for submissions
Join the Movement to Advance Mental Health and Wellbeing!
Advances in Clinical and Experimental Medicine invites you to submit your cutting-edge research and articles on Mental Health and Well-being. We are seeking groundbreaking contributions that push the boundaries of understanding, treating, and promoting mental well-being.
Handling Editors
Prof. Raúl Juárez-Vela (Group of Research in Care (GRUPAC), Faculty of Health Sciences, University of La Rioja, Logroño, Spain; ORCID 0000-0003-3597-2048) raul.juarez@unirioja.es
Topics of interest include, but are not limited to:
- Innovative therapeutic interventions
- Strategies for prevention and promotion of mental well-being
- Impact of mental health on quality of life
- New approaches in the treatment of mental disorders
- Studies on the relationship between mental health and physical diseases
Why publish with us?
- Global Visibility: Reach a wide international audience with your work
- Rigorous Review: Benefit from our high-quality peer review process
- Academic Impact: Make a significant contribution to a vital and dynamic field
Submission process
As a first step, we ask for submissions of an Expression of Interest with an Abstract of original papers outlining the themes above to Adv Clin Exp Med Section Editor: raul.juarez@unirioja.es
The Section Editor, jointly with the Editor-in-Chief, will review all submissions and select those that will be invited to submit a full paper. The submission process will then follow the regular Adv Clin Exp Med. online process. All manuscripts will be sent to at least two independent reviewers.
Dates and fees
- Submission of Expression of Interest until December 31, 2025, to raul.juarez@unirioja.es
- Invitation to submit a full paper by January 31, 2026;
- Submission of full paper by March 31, 2026.
If accepted, Authors will be required to pay a fee (https://advances.umw.edu.pl/en/article-processing-charges/) to cover publication costs;
For selected Authors (outstanding experts), it is possible to reduce or even cancel the publication fee.
Submit your manuscript today and join the global conversation on enhancing mental health and well-being. Visit our website for more details on the submission process.
We eagerly anticipate your valuable contributions!
¡Únete al movimiento para avanzar en la salud mental y el bienestar!
Advances in Clinical and Experimental Medicine te invita a enviar tu investigación y artículos de vanguardia en el campo de la salud mental y el bienestar. Buscamos contribuciones innovadoras que amplíen los límites de la comprensión, el tratamiento y la promoción del bienestar mental.
Editores a cargo
Prof. Dr. Raúl Juárez-Vela (Grupo de Investigación en Cuidados (GRUPAC), Facultad de Ciencias de la Salud, Universidad de La Rioja, Logroño, España; ORCID 0000-0003-3597-2048) raul.juarez@unirioja.es
Los temas de interés incluyen, pero no se limitan a:
- Intervenciones terapéuticas innovadoras
- Estrategias para la prevención y promoción del bienestar mental
- Impacto de la salud mental en la calidad de vida
- Nuevos enfoques en el tratamiento de trastornos mentales
- Estudios sobre la relación entre la salud mental y las enfermedades físicas
¿Por qué publicar con nosotros?
- Visibilidad global: Alcanza una amplia audiencia internacional con tu trabajo.
- Revisión rigurosa: Benefíciate de nuestro proceso de revisión por pares de alta calidad.
- Impacto académico: Haz una contribución significativa a un campo vital y dinámico.
Proceso de envío
Como primer paso, solicitamos el envío de una Expresión de Interés con un resumen de artículos originales que aborden los temas mencionados al Editor de Sección de Adv Clin Exp Med: raul.juarez@unirioja.es
El Editor de Sección, junto con el Editor en Jefe, revisará todas las presentaciones y seleccionará aquellas que serán invitadas a enviar un artículo completo. El proceso de envío seguirá el proceso en línea regular de Adv Clin Exp Med. Todos los manuscritos serán enviados a al menos dos revisores independientes.
Fechas y tarifas
- Envío de la Expresión de Interés hasta el 31 de diciembre de 2025 a raul.juarez@unirioja.es
- Invitación para enviar un artículo completo antes del 31 de enero de 2026;
- Envío del artículo completo antes del 31 de marzo de 2026.
Si se acepta, los autores deberán pagar una tarifa (https://advances.umw.edu.pl/en/article-processing-charges/) para cubrir los costos de publicación;
Para autores seleccionados (expertos destacados), es posible reducir o incluso cancelar la tarifa de publicación.
Envía tu manuscrito hoy y únete a la conversación global sobre el mejoramiento de la salud mental y el bienestar. Para más detalles sobre el proceso de envío, visita nuestro sitio web: https://advances.umw.edu.pl/en/home.
¡Esperamos con ansias tus valiosas contribuciones!
International Scientific Conference FAMILY – HEALTH – DISEASE
The event is aimed at academics and practitioners supporting patients in the process of diagnosis, treatment and recovery: health care professionals - members of interdisciplinary therapeutic teams (doctors, nurses, physiotherapists, dieticians, psychologists, occupational therapists and medical caregivers, diagnosticians, management staff managing medical entities), research and teaching staff of universities, students of scientific circles, participants of doctoral schools and all persons interested in the above mentioned topics.
Our journal has become a media partner of this conference.
.png)
Seasonal greetings – wishing you a peaceful and joyful Easter time!
In this season of renewal and reflection, we wish you peace, well-being, and moments of joy—both personally and professionally. May this time bring inspiration, balance, and new beginnings for your research and beyond.
In many countries, Easter celebrations will start shortly or are already underway. One of the most important symbols of Easter is the egg. It has always held particular symbolic significance, partly because it is a visual shorthand for new life and unhatched potential. The egg brings hope and purity. It is a symbol of fertility and the circle of life. In some Asian cultures, the egg is seen as a symbol of luck and wealth. Ancient traditions used to link the egg to the creation of the universe, suggesting that the Earth itself may have been born out of an egg. There is also an interesting contrast between the soft interior and the protective tough exterior, evoking ideas of protection and hidden secrets.
In our Easter wishes, we also want to use the symbol: Let your ideas and discoveries be like a baby bird hatching from an egg, a new life in the world of global science. Other people witness this hatching; they await your contributions and value your devotion.
With warmest regards,
The Editorial Team of Advances in Clinical and Experimental Medicine
New call for submission
Out in Health: Health Equity and Innovations in LGBT+ Care
Call for submissions of an Expression of Interest for an Adv Clin Exp Med Special Collection on LGBT+ Health Equity and Innovation
Handling Editors
Assoc. Prof. Michał Czapla (Division of Scientific Research and Innovation in Emergency Medical Service, Department of Emergency Medical Service, Faculty of Nursing and Midwifery, Wroclaw Medical University, Wrocław, Poland; Group of Research in Care (GRUPAC), Faculty of Health Sciences, University of La Rioja, Logroño, Spain; ORCID 0000-0002-4245-5420) michal.czapla@umw.edu.pl
Dr. Anthony Dissen (Stockton University, Galloway, USA; ORCID 0000-0003-0828-387X) anthony.dissen@stockton.edu
Assoc. Prof. Bartłomiej Stańczykiewicz (Division of Consultation Psychiatry and Neuroscience, Department of Psychiatry, Faculty of Medicine, Wroclaw Medical University, Poland; ORCID 0000-0001-9221-3502) bartlomiej.stanczykiewicz@umw.edu.pl
This Call for Submissions invites Expressions of Interest for a Special Collection of Advances in Clinical and Experimental Medicine, focusing on LGBT+ health equity and innovation.
LGBT+ individuals around the world face unique and persistent health disparities driven by stigma, discrimination, and systemic exclusion from healthcare systems. These inequities result in significantly worse physical and mental health outcomes and limit access to inclusive, culturally competent care.
This Special Collection will offer researchers and clinicians an opportunity to publish original research, meta-analyses, and review articles that address these disparities and propose inclusive, personalized, and innovative solutions to improve health outcomes for LGBT+ populations.
This Call welcomes submissions on (but not limited to):
- Mental Health & Wellbeing
- Sexual & Reproductive Health
- Transgender & Gender-Diverse Health
- Equity in Healthcare Access
- Social Determinants of Health
- Stigma & Healthcare Avoidance
- Community & Public Health Initiatives
- Intersectionality in Health
Submission process
As a first step, we ask for submissions of an Expression of Interest with an Abstract of original papers outlining the themes above to Adv Clin Exp Med Section Editor: michal.czapla@umw.edu.pl and anthony.dissen@stockton.edu and bartlomiej.stanczykiewicz@umw.edu.pl.
The Section Editor, jointly with the Editor-in-Chief, will review all submissions and select those who will be invited to submit a full paper. The submission process will then follow the regular Adv Clin Exp Med. online process. All manuscripts will be sent to at least two independent reviewers.
Dates and fees
- Submission of Expression of Interest until September 30, 2025, to michal.czapla@umw.edu.pl and anthony.dissen@stockton.edu and bartlomiej.stanczykiewicz@umw.edu.pl
- Invitation to submit a full paper by October 31, 2025;
- Submission of full paper by January 31, 2026;
If accepted, Authors will be required to pay a fee (https://advances.umw.edu.pl/en/article-processing-charges/) to cover publication costs;
For selected Authors (outstanding experts), it is possible to reduce or even cancel the publication fee.
We look forward to a wide variety of truly global papers and experiences that will push worldwide science to the next level!
Communicate with respect
As editors, we are committed to upholding the highest standards of professionalism, civility, and respect in all our interactions with members of the scientific community and the general public. At Advances in Clinical and Experimental Medicine, we believe that only relationships grounded in mutual respect foster trust and enable the delivery of high-quality scientific publishing services to the communities we serve.
All members of our editorial team are expected to maintain a professional and respectful attitude at all times when engaging with authors, reviewers, and readers. We equally expect that individuals interacting with our editorial office adhere to the same standards of behavior. We do not tolerate aggressive or offensive behavior from any party, including any form of harassment, bullying, discrimination, or unfounded allegations directed against our editorial staff.
Complaints concerning alleged racism, sexism, or other forms of discrimination must be substantiated with specific quotations from written communications received from editors or reviewers of Adv Clin Exp Med; otherwise, such complaints may be regarded as a form of harassment. Any reported case of alleged discrimination will be carefully reviewed by the Editors, and a formal response will be provided to the person submitting the report.
We reserve the right to escalate serious cases to the appropriate institutional authorities or legal entities if warranted. Furthermore, we may suspend or permanently discontinue communication and collaboration with individuals who repeatedly or seriously breach this policy.
Fostering respectful and professional editorial communication
At Advances in Clinical and Experimental Medicine, we strive to maintain a working environment rooted in professionalism, mutual respect, and openness. This applies equally to all individuals involved in the publication process, including authors, peer reviewers, and editors.
Academic quality is inseparable from respectful collaboration. For this reason, the tone and content of our editorial correspondence - particularly in email communication, where nuances can sometimes be misinterpreted - are shaped by the values of clarity, helpfulness, and fairness. These standards reflect the expectations of the international scientific community and our commitment to responsible publishing.
Our editorial team is dedicated to:
• Communicating with courtesy and clarity, especially in feedback to authors and reviewers
• Offering constructive suggestions that help enhance scientific work
• Remaining mindful of cultural, personal, and worldview differences
• Upholding strong editorial ethics and transparency in every interaction
If at any point you believe that our communication falls short of these values, please feel free to reach out in confidence to the Editor-in-Chief, Prof. Donata Kurpas (donata.kurpas@umw.edu.pl), or the Deputy Editor, Prof. Robert Śmigiel (robert.smigiel@umw.edu.pl).
We firmly believe that mutual respect and professionalism are key to building an academic journal that earns the trust of its contributors and readership.
Our new manuscript withdrawal policy
Authors may withdraw their manuscript at any stage of the editorial process. However, 2 conditions must be met for a withdrawal request to be processed:
- A clear and specific reason for withdrawal must be provided – both in the Editorial System and in the withdrawal statement.
- All authors must consent to the withdrawal. A statement signed by all authors should be scanned and submitted as a PDF file to the editorial office at [redakcja@umw.edu.pl] and/or uploaded to the Editorial System as an Additional File.
Until these conditions are fulfilled, the manuscript cannot be considered withdrawn.
Social Prescribing Day – March 19, 2025
Social Prescribing Day is an annual celebration of the people, organizations and communities who make social prescribing happen. Since 2019, thousands of local, national and international organizations, link workers, medical professionals, academics and students have taken part across the world. Every year, we have joined together to hold events, share ideas and highlight the impact of social prescribing on people and communities. Together, we want to raise awareness of what social prescribing is, how it works, and how it changes lives.
What is social prescribing?
The accepted international definition of social prescribing is “a means for trusted individuals in clinical and community settings to identify that a person has non-medical, health-related social needs and to subsequently connect them to non-clinical supports and services within the community by co-producing a social prescription – a non-medical prescription, to improve health and well-being and to strengthen community connections.”
Many things that affect our health and wellbeing cannot be treated by doctors or medication alone – like loneliness, isolation or stress due to problems with housing or cost of living pressures. Social prescribing is a way of connecting people to non-medical support to address these issues and other unmet needs. It means working closely with individuals to understand their needs and develop a personalized plan to improve their health and wellbeing. This can involve:
– Helping someone who is isolated to join a befriending group, an art class or a community gardening project, based on what matters to them
– Connecting someone struggling with financial pressures and stress to a service that helps them manage debt or claim benefits
– Supporting someone with dementia to join a dementia choir, enabling them to maintain speech and language and connect with others
– Working with someone with high blood pressure to take up a form of exercise that they’re comfortable with
– Supporting someone who is out of work to connect with support schemes and employment opportunities.
New article category – study protocol
Study Protocol articles provide a comprehensive overview of the design of prospective research, aiming to facilitate the dissemination of ongoing studies and enhance transparency in clinical and biomedical research. These articles outline the hypothesis, rationale, methodology, and ethical considerations of the study, serving as a valuable resource for researchers and clinicians.
We consider study protocols for proposed or ongoing prospective clinical research, provided that participant recruitment has not been completed at the time of submission. Protocols for retrospective studies, feasibility studies, or pilot studies are not eligible. Additionally, study protocols will not be considered if any articles reporting data from the study have already been published or are under review.
Submission Guidelines:
- Study Protocol articles undergo peer review.
- The manuscript should not exceed 3,500 words.
- A maximum of 10 figures and/or tables may be included.
- The paper should follow a 5-part structure: Highlights, Introduction, Methodology, Discussion, Conclusion.
- The abstract should not exceed 300 words and follow a 4-part structure: Introduction, Methodology, Discussion, Conclusion.
- Formal ethical approval of an appropriate ethics committee is mandatory.
- For clinical studies, registration in a public clinical trial registry is mandatory before manuscript submission.
- Authors are strongly encouraged to follow the SPIRIT guidelines (SPIRIT Statement).
This structured approach ensures that Study Protocol articles contribute meaningfully to the research community while maintaining rigorous academic and ethical standards.
Editor-in-Chief's Choice
Starting this year, the journal's website will regularly feature publications selected by the Editor-in-Chief for their potential to drive meaningful changes in healthcare and improve patient outcomes worldwide. We will provide specially curated content and podcasts to engage both researchers and the broader community, drawing attention to key issues of importance.
Please join us at Editor-in-Chief's Choice!
Chinese New Year
The Year of the Wood Snake – the new year in Chinese zodiac – begins on January 29, 2025. The snake (蛇) is the sixth of the twelve-year cycle of animals which appear in the Chinese zodiac related to the Chinese calendar. The Year of the Snake is associated with the Earthly Branch symbol (巳).
The Snake represents wisdom, knowledge, intelligence, intuition and creativity. Snakes are also associated with good luck, prosperity, fertility and longevity. Snakes are also revered for their ability to shed their skin and renew themselves, symbolizing transformation and rebirth.
In Chinese Taoist and Traditional Chinese medicine thought, Wood attributes are considered to be strength and flexibility, as with bamboo. The wood element seeks ways to grow and expand. Wood heralds the beginning of life, dawn, springtime and buds, sensuality and fecundity. It is also associated with qualities of warmth, generosity, cooperation, and idealism. In Chinese medicine, wood is associated with negative feelings of anger, hopelessness and positive feelings of optimism, courage, patience and the virtue of benevolence (Ren 仁).
These characteristics should also inspire our understanding of medicine. Like the snake sheds their skin and lives on, the physician helps the patients in leaving the disease – like the old skin – behind them. Similarly, like wood is flexible and full of life (understood both literally and metaphorically), medical researchers must be flexible and proactive in their search for understanding and curing illnesses – in their quest for truth. Chinese forests – especially in Southern China – are characterized by dense vegetation. Tree branches become intertwined and animals can wander from one tree to another without even touching the ground. There are also snakes capable of such a mode of locomotion, like the ornate flying snake or the Chinese green snake. The scientific community should be like such a forest – a vast network of people supporting each other, with the common goal of advancing human quality of life.
We wish you all the best in the Year of the Wood Snake – the celebrations will be held in China, Taiwan, Singapore, and in Chinese communities around the world, but the symbolism of this Chinese zodiac sign can inspire all people, regardless of their ethnicity, culture and language.
.jpg)
Highlights
We are introducing a new section – “Highlights” – in papers published in our journal. The “Highlights” section is the first in the main body of the paper – it should appear before the Background/Introduction section. The "Highlights" section provides a concise summary of the most significant findings and the relevance of the article. It aims to help readers quickly understand the key aspects of the study and enhance the article’s visibility in scientific databases.
Guidelines for preparing “Highlights”
PROSPERO – a registry for protocols of systematic reviews
We strongly encourage authors of systematic reviews to register their detailed protocols before data extraction commences in a public registry such as PROSPERO (https://www.crd.york.ac.uk/prospero/). The number obtained during the registration should be provided in the submitted paper – both in the Materials and Methods section and at the end of the main body of the manuscript – using the following disclaimer:
This systematic review has been registered in the PROSPERO registry under No. [NUMBER PROVIDED BY PROSPERO].
More information about PROSPERO here:
https://www.crd.york.ac.uk/prospero/documents/Registering%20a%20review%20on%20PROSPERO.pdf
Prospective registration of systematic reviews promotes transparency, helps reduce the potential for bias and serves to avoid unintended duplication of reviews. A single point of access to information about ongoing reviews should also help avoid the unintended duplication of reviews and wasting of resources, a consideration that is more important than ever in the current economic climate.
Registration allows researchers to comply with PRISMA and provides a permanent public record of their planned methods. It may also help raise awareness of their review. Use of the unique registration number may be useful in helping track subsequent use or citation of the review to monitor its impact.
Commissioning and funding organizations can utilize PROSPERO to identify ongoing and unpublished reviews to help them avoid unplanned duplication and waste of financial resources.
Guideline developers could use information about forthcoming reviews to assist in the planning and timing of guideline development.
Peer reviewers will be able to link a manuscript to the corresponding registration record (and, where available, through to the full protocol). The registration record and/or the protocol may provide important additional information about, and clarity regarding, the methods that are absent from the manuscript. It could also speed the process because some issues of clarification that would otherwise be sent back to the authors as questions could be resolved by checking the registration record or protocol, thereby circumventing a round of question-and-response between reviewers, journal editors and authors..
The most active reviewer for our journal in the year 2024
We are pleased to announce that in the past year, the most active reviewer for Adv Clin Exp Med was Dr. Talha Bin Emran, who performed as many as 94 reviews.
Please accept our congratulations and gratitude.
New call for submissions: From Bench to Bedside: Advances in Neuroinflammation and CNS Disorder Research
The editors of this special collection invite submissions exploring the latest advances in clinical and experimental research on neuroinflammation in the central nervous system (CNS). Neuroinflammation is at the forefront of neuroscience, shaping our understanding of CNS disorders such as neurodegenerative disease, psychiatric disorders and traumatic brain injuries. This collection aims to unite diverse perspectives, fostering insights into the complex cellular and molecular mechanisms driving neuroinflammatory processes. We encourage the submission of original research, meta-analyses and comprehensive review articles that shed light on diagnostic, therapeutic and mechanistic aspects of CNS inflammation.
We are particularly interested in manuscripts that explore the interplay between immune cells, neurons and glia, with a focus on translational research. Contributions detailing innovative diagnostic approaches, therapeutic targets or computational models are highly welcome. Join this effort to advance the boundaries of neuroinflammation research and contribute to groundbreaking findings that bridge laboratory and clinical neuroscience.
New call for submissions: Obesity Over the Life Span
This Special Issue of Adv Clin Exp Med will provide focused, comprehensive coverage of key clinical and public health issues related to obesity. Over the last 3 decades, the global prevalence of obesity has more than doubled, reflecting profound shifts in lifestyle, diet and environmental determinants of health. Obesity has become the dominant form of malnutrition worldwide, contributing to a broad spectrum of health complications, including chronic diseases, functional impairments and reduced quality of life.
This Call for Submissions aims to provide researchers and clinicians with an opportunity to publish original research, meta-analyses and review articles addressing recent advances in the epidemiology, prevention, and treatment of obesity. Emphasis will be placed on multidisciplinary approaches, personalized management strategies, and the life-course perspective of this growing epidemic.
_page-0001.jpg)
Authorship and AI tools – COPE position statement
The use of artificial intelligence (AI) tools, such as ChatGPT or Large Language Models, in research publications is expanding rapidly. COPE joins organisations, such as WAME and the JAMA Network, among others, to state that AI tools cannot be listed as an author of a paper.
AI tools cannot meet the requirements for authorship, as they cannot take responsibility for the submitted work. As non-legal entities, they cannot assert the presence or absence of conflicts of interest nor manage copyright and license agreements.
Authors who use AI tools in the writing of a manuscript, production of images or graphical elements of the paper, or in the collection and analysis of data, must be transparent in disclosing in the Materials and methods (or similar section) of the paper how the AI tool was used and which tool was used. Authors are fully responsible for the content of their manuscript, even those parts produced by an AI tool, and are thus liable for any breach of publication ethics.
The above statement has been published by the Committee on Publication Ethics (COPE) and is available on the official website of COPE: Authorship and AI tools
Suggested peer reviewers
Authors of each submitted manuscript are required to suggest 3 potential peer reviewers. Fulfilling this requirement is paramount to alleviating the peer-review crisis in scientific publishing and is mandatory.
Suggested reviewer has to be:
- from a different country than any of the authors;
- a specialist in a relevant field of medicine (There have been instances where the recommended reviewers were from completely unrelated scientific fields, sometimes not even within medicine.).
Please provide the following information concerning the suggested reviewers:
- name;
- institutional e-mail;
- link to the institutional personal page of the reviewer (if possible).
This would facilitate proper identification and traceability to their professional profile and respective institutions.
The suggested reviewers cannot have a conflict of interest as described here:
https://www.journals.elsevier.com/journal-of-systems-and-software/policies/conflict-of-interest-guidelines-for-reviewers
We work with the best!
Experts from Stanford University, under the supervision of Prof. John Ioannidis, in cooperation with Elsevier, prepared the 7th version of a publicly available database of top-cited scientists that provides standardized information on citations, h-index, co-authorship-adjusted hm-index, citations to papers in different authorship positions, and a composite indicator (c-score). This database includes a list of the top 2% most widely cited scientists in various disciplines. Separate data are shown for career-long and, separately, for single recent year impact. Metrics with and without self-citations and the ratio of citations to citing papers are given. The selection is based on the top 100,000 scientists by c-score (with and without self-citations) or a percentile rank of 2% or above in the sub-field. The most recent (7th) version is based on the contents of Scopus from October 1, 2023, updated to end of citation year 2022.
This list shows how many top researchers are in our Scientific Committee and among our section editors – 15! It’s clear proof that experienced and renowned specialists want to work with us and contribute to the development of Advances in Clinical and Experimental Medicine!
The congratulations go to: Simone Battaglia, Maria Bujnowska-Fedak, Antonio Cano, Breno Diniz, Erwan Donal, Christos Lionis, Adam Matkowski, Monika Sawhney, James E. Sharman, Jamil A. Shibli, Jacek Szepietowski, Masaru Tanaka, Izabella Uchmanowicz, László Vécsei, and Hao Zhang.
The database is available here:
https://elsevier.digitalcommonsdata.com/datasets/btchxktzyw/7
New Index Copernicus Value
The Index Copernicus Value (ICV) of Advances in Clinical and Experimental Medicine has increased from 161.11 for 2022 to 171.00 for 2023. Special thanks go to all our authors, reviewers and section editors, whose hard work, commitment and competence have made this achievement possible.
Index Copernicus Value is an evaluation standard for scientific journals. Its unique character is guaranteed by the fact that it enables the annual organization of the list of scientific journals from all around the world within the ICI Journals Master List. It also gives – in the extended version – specific guidelines concerning functional areas of a scientific journal that have to be improved to increase citation rate. The ICV index has been recognized by, e.g., public administration authorities, scientific units and other subjects associated with science.
Index Copernicus (IC) is an online database of user-contributed all information, including profiles of scientists, as well as of scientific institutions, publications and projects established in 1999 in Poland, and operated by Index Copernicus International. The database, named after Nicolaus Copernicus (who triggered the Copernican Revolution), has several assessment tools to track the impact of scientific works and publications, individual scientists, or research institutions.
EndNote and references
If you use EndNote software to manage your references, you can format them automatically into our required reference format (AMA citation style) using this file.
- Download the style file.
- Double-click the style file. It should open in EndNote.
- In EndNote, go to “File Menu” and choose “Save As”. Replace the word “copy” with your style’s name and click “Save”.
- Click on “File Menu” and choose “Close Style”.
EndNote: Finding the American Medical Association (AMA) Style
EndNote: Install Additional Output Styles (clarivate.com)
Our new policy concerning data sharing
All original papers and research letters submitted to Adv Clin Exp Med since August 15, 2024, will be subject to our new policy concerning data sharing.
Adv Clin Exp Med requires the Authors of all original papers and research letters to make all data necessary to replicate the results of their study publicly available without restriction when the paper is submitted to the journal (relevant information must be registered in the Editorial System at the time of submission). The following provisions apply only to original papers (including research letters). They do not apply to reviews and meta-analyses.
Change in the rules of incentives for reviewers
Since January 1, 2021, our Reviewers receive 5 points for each review prepared for our journal. A total of 20 points allows them to publish an article in Advances in Clinical and Experimental Medicine free of charge, provided that they are the first or the last author of a given article. Since July 1, 2024, The points are valid for 2 years (24 months) counting from the day when a paper authored by our reviewer is initially accepted for publication and a requirement for paying APC appears (e.g., when the paper was initially accepted on July 1, 2024, 20 points must have been amassed within previous 24 months, that is from July 1, 2022, to June 30, 2024).
If an author knows or supposes that they are eligible for an APC waiver, they should contact the Managing Editor: marek.misiak@umw.edu.pl [alternative e-mail for Chinese authors: marek.misiak@friend.pl] – the Editorial System does not always remind editors about such eligibility.
Our copyright declaration
The Author/Author(s) declare that:
a) they are copyright holders of the scientific work/publication;
b) they are entitled to dispose of copyright for the concluded license/publishing agreement with the Wroclaw Medical University;
c) they created the work/publication on their own;
d) the work/publication does not violate the rights of third parties.
If a third party files a claim against Wroclaw Medical University as a result of the inconsistency of the Author's statements or assurances, the Author is obliged to immediately cover the full amount of all damages, costs, and expenses incurred by Wroclaw Medical University in connection with such claims. This includes damages and costs awarded by a competent court or resulting from the content of the settlement concluded with the aggrieved party, as well as costs of legal services.
Our rules concerning the usage of AI tools
These guidelines only refer to the writing process (i.e., generating text using an AI tool), and not to the use of AI tools to analyze and draw insights from data as part of the research process. They do not apply to the use of basic tools for checking grammar, spelling, references, etc.
Authors are allowed to use generative AI and AI-assisted technologies in the writing process before submission, but only to improve the language and readability of their paper and with the appropriate disclosure. Applying the technology should be done with human oversight and control, and authors should carefully review and edit the result, as AI can generate authoritative-sounding output that can be incorrect, incomplete or biased. AI and AI-assisted technologies should not be listed as an author or co-author, or be cited as an author. Authorship implies responsibilities and tasks that can only be attributed to and performed by humans. Please note that authors are ultimately responsible and accountable for the contents of the work.
Increase in article-processing charge (APC)
Advances in Clinical and Experimental Medicine is a journal published in a golden open access model – each published paper is available online at no cost, without any embargos, subscriptions or paywalls. Everyone can access and download it without any restrictions. However, such a model requires an article-processing charge (APC) since the journal receives no payments from the readers. The APC is payable per the accepted article. Our APC is calculated to contribute to the costs associated with the publication process from peer review of the submitted manuscript, through to copy-editing and typesetting, to online hosting and dissemination of the published article. It is a prerequisite to ensure the unrestricted dissemination of your research in the scientific community and beyond. Therefore, from March 1, 2024 [Friday], 0:01 CET, our APC will increase.
The publication fee for manuscripts submitted since March 1, 2024, is:
1600 EUR / 6900 PLN for all types of papers.
We DO NOT charge publication fees for invited editorial and editorial commentaries.
If the paper was submitted by February 29, 2024, the following APCs apply:
– 990 EUR / 4900 PLN for original papers and meta-analyses;
– 700 EUR / 3500 PLN for reviews;
– 350 EUR / 1750 PLN for research-in-progress (RIP) papers and research letters.
The publication fee for manuscripts submitted until January 31, 2023, is:
– 700 EUR / 3500 PLN for original papers, meta-analyses and reviews;
– 350 EUR / 1750 PLN for research-in-progress (RIP) papers and research letters.
https://advances.umw.edu.pl/en/article-processing-charges/
You do the research – we take care of the text
There are additional fees for the following optional services (if ordered by the Authors of the manuscript accepted for publication):
- 200 EUR / 880 PLN for linguistic editing;
- 200 EUR / 880 PLN for technical editing.
Services offered
Linguistic editing ensures that the English language of your manuscript is of the academic standard required for publication in our journal. It comprises correcting grammar, punctuation and spelling errors, pointing to inconsistencies, as well as removing or reformulating awkward or ambiguous sentences, while keeping, where possible, your voice and choice of words. We also suggest discipline-specific terms. In the proof sent to you, all our comments and doubts are clearly marked, so that you could make the necessary corrections.
Technical editing ensures that the structure of your manuscript follows the Adv Clin Exp Med house style. We reformat references (both in the text and the whole reference list) and look for missing information in the reference section. We improve the overall presentation by revising titles/subtitles, font, spacing, text alignment, and paragraph structure. We also edit equations and tables, and produce publication-ready figures that clearly communicate your research to readers. Figure editing enhances your charts and graphs, as well as graphical abstracts; it comprises revising the text included, colors, shading, border, size, resolution, and file type.
You can choose either or both of the abovementioned optional services, or decline them. When submitting the manuscript to Adv Clin Exp Med via the Editorial System, you will be provided with special checkboxes to select if needed. Following the acceptance of your article for publication, you will be asked to pay the basic APC and the additional fees for the chosen editing services.
Please be informed that the articles finally published in Adv Clin Exp Med must comply with the high standards of the journal.
More information: Managing Editor [marek.misiak@umw.edu.pl]
Our new requirements concerning figures
We implemented new requirements regarding figures – they stem from stipulations issued by databases and digital archives in which our journal is indexed.
We accept up to 10 figures (2 figures in Research letters). Overtly complex figures will be divided into smaller ones and the number of figures will be counted again. A single figure can have no more than 6 panels (A–F). One panel means one chart – multiple small charts cannot form one panel.
All elements of each figure must be legible when viewed on an A4 page in a PDF file in full-screen mode, without zooming. Overtly complex figures with multiple charts/graphs combined into one panel cannot fulfill this requirement. Figures of low quality cannot be published, and consequently, papers with low-quality figures will not be published, even if accepted by peer reviewers.
Figures should be placed in separate files, not pasted into the main body of the text. Name your figure files with "Fig" and the figure number, e.g., Fig.1.tiff.
References to Figures should be placed according to the sequence of citing them in the manuscript. The text should include references to all figures.
Each figure should have a concise, self-explanatory caption describing accurately what the figure depicts. Captions for the figures should be placed at the end of the main body of the text. Do not embed the legend in the figure file. When applicable, be sure that both the figure captions and the figures themselves contain corresponding labels for multiple parts. Identify all elements found in the figure in the figure caption, and use boxes, circles, etc., as coordinate points in graphs. If any magnification is used in the photographs, indicate this by using scale bars within the figures themselves. All abbreviations used in a given table/figure should be explained below it or in the caption, even if a given abbreviation has already been explained in the text.
If Authors used in the work any figures, photographs, charts, tables, etc. which are not their work, and are protected by the copyright law, they shall be obliged to provide the Publisher with a written authorization to use such materials issued by the author’s economic rights holders. Identify previously published material by giving the original source in the form of a reference citation at the end of the figure caption.
OUR NEW TECHNICAL REQUIREMENTS:
https://advances.umw.edu.pl/source/Adv%20Clin%20Exp%20Med-figures-technical%20requirements.pdf
Altmetrics
We’ve chosen to embed Altmetric Badges on our publications to help authors track the attention their research is receiving. By tracking unique identifiers such as DOIs, Altmetric collects article-level metrics and online conversations around articles published in Adv Clin Exp Med. Online mentions that contain links to the abstract landing page are picked up and collated, and the result is the Altmetric Attention Score and Badge.
You will find the Altmetric Badge at the top of each article’s page. When you click on the Altmetric Badge, you will be directed to the Altmetric Details Page, which will show you every mention for your article across Twitter, blogs, mass media outlets, Facebook, and more. View this video for an overview of the Altmetric Details Page.
Our rules concerning corrections, retractions and removals
The editorial office of Adv Clin Exp Med will carefully consider complaints, appeals and allegations in line with guidance from the Committee on Publication Ethics (COPE). This applies both pre- and post-publication. Authors, readers or institutions can lodge complaints.
https://advances.umw.edu.pl/en/complaints-corrections-retractions
Our rules concerning appeals
The authors have the right to appeal against a rejection from Adv Clin Exp Med. An appeal is an extension of the peer review process, and the same ethical standards apply, so a request should not be submitted whilst the manuscript in question is under consideration by another publication.
https://advances.umw.edu.pl/en/appeals
Our rules concerning commentaries and discussions
Commentaries are short articles that outline an observation on a published article. If a researcher wishes to comment on a paper published in Adv Clin Exp Med, before formal submission, they should contact the journal with a pre-submission enquiry: [Managing Editor Marek Misiak, marek.misiak@umw.edu.pl OR marek.misiak@friend.pl]. If approved for submission as a Commentary, they will then be invited to publish a brief commentary article, which will be bi-directionally linked to the original paper it discusses. A Commentary should consist of up to 1500 words, excluding references, and at most 2 tables or figures (2 tables and 2 figures at most in one paper). The number of references is not limited. A Commentary can have up to 2 authors. Commentaries should be written in a neutral tone and must relate to the original published article. All such articles considered for publication will be subject to peer review, and the decision to accept or reject an article is at the editor’s discretion.
https://advances.umw.edu.pl/en/commentaries-and-discussions
DORA
ACEM is a signatory of San Francisco Declaration on Research Assessment (DORA), which intends to halt the practice of correlating the journal impact factor to the merits of a specific scientist's contributions. Such practice creates biases and inaccuracies when appraising scientific research. It also states that the impact factor is not to be used as a substitute measure of the quality of individual research articles, or in hiring, promotion, or funding decisions. It has become a worldwide initiative covering all scholarly disciplines and all key stakeholders including funders, publishers, professional societies, institutions, and researchers. We encourage all individuals and organizations who are interested in developing and promoting best practice in the assessment of scholarly research to sign DORA.
Its objectives are:
1. Raise awareness. To call attention to new tools and processes in research assessment and the responsible use of metrics that align with core academic values and promote consistency and transparency in decision-making.
2. Facilitate implementation. To aid development of new policies and practices for hiring, promotion, and funding decisions.
3. Catalyze change. To spread research assessment reform broadly by working across scholarly disciplines and globally.
4. Improve equity. To call for broader representation of researchers in the design of research assessment practices that directly address the structural inequalities in academia.
How Journals and Publishers Can Help to Reform Research Assessment?
Using bar and line graphs to present statistical data
Figures in scientific publications are critically important because they often show the data supporting key findings. However, small sample size studies rarely include scatterplots, box plots and histograms that allow readers to critically evaluate continuous data. Most papers present continuous data as bar and line graphs. This is problematic, as many different data distributions can lead to the same bar or line graph. The full data may suggest different conclusions from the summary statistics.
This issue is concisely discussed [with examples] in this paper:
https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.1002128
It is also worthy to read this paper:
https://www.nature.com/articles/520589f
Support from the Ministry
Our journal has received financial support within the “Social Responsibility of Science – Support for Academic Publishing” project based on agreement No. RCN/SP/0584/2021 from the resources of Ministry of Science and Higher Education.
Scientific Social Responsibility programs – Science for All – constitute an important offer for society. They aim at identifying opportunities, supporting dialogue and engaging large groups of stakeholders. Science for All increases the efficiency and effectiveness of activities in science and research areas, implementing the University’s Third Mission.
Not only does Science for All popularize and disseminate science but also stimulates cognitive curiosity and integrate local communities with academia. The Science for All initiatives are supposed to equal educational opportunities and reach those parts of the country where academic and scientific activity has not existed so far.
DOAJ
The editorial office of Advances in Clinical and Experimental Medicine proudly informs that the journal has been accepted into Directory of Open Access Journals (DOAJ) and is indexed in this database. This fact confirms our integrity regarding publication ethics and clear rules for authors.
